95 completed, 2 active not recruiting, 2 recruiting, 2 unknown. 46 Phase 2, 34 Phase 3, 18 Phase 4, 13 Phase 1.
Follow Meningococcal Vaccines: new trials by email Literature Review of Meningococcal Vaccines trials Research Report on Meningococcal Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children AltSonflex1-2-3, Menveo, Infanrix hexa - Diarrhoea | Phase 2 | Not yet recruiting | GlaxoSmithKline | 528 | 2026-01-02 | 2026-01-06 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old EG-MCV4, Menveo - Meningococcal Infections | Phase 2 / Phase 3 | Recruiting | EyeGene Inc. | 1123 | 2025-10-15 | 2025-12-01 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2024-01-15 | 2026-09-21 |
| Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunisation, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1215 | 2023-10-31 | 2026-01-13 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV) - Meningococcal Immunisation, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1528 | 2023-03-27 | 2026-01-21 |
| Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old EuNmCV-5, Menveo - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2023-02-28 | 2023-12-20 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
| R21/Matrix-M in African Children Against Clinical Malaria R21/Matrix-M, Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine - Malaria | Phase 3 | Active not recruiting | University of Oxford | 4800 | 2021-04-29 | 2026-02-23 |
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections | Phase 4 | Recruiting | Thomas Benfield | 55 | 2021-04-28 | 2021-05-06 |
| Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine MenABCWY vaccine, Placebo, MenACWY vaccine - Meningitis, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1250 | 2021-01-25 | 2024-07-03 |
| Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-09-01 | 2021-10-07 |
| Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 945 | 2020-08-25 | 2025-03-04 |
| Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 3657 | 2020-08-14 | 2024-03-05 |
| Investigating a Vaccine Against COVID-19 ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost - Coronavirus | Phase 2 / Phase 3 | Completed | University of Oxford | 10811 | 2020-05-28 | 2025-09-03 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningococcal Immunisation (Healthy Volunteers) | Phase 3 | Completed | Sanofi | 360 | 2020-05-22 | 2025-09-15 |
| Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors Menactra - Preventive Immunization; Meningitis | Phase 4 | Unknown | Brigham and Women's Hospital | 102 | 2020-03-12 | 2022-11-15 |
Showing 20 of 103. Sign in to see all of them.
Meningococcal Infections (64) · Meningitis (48) · Meningitis, Meningococcal (30) · Whooping Cough (6) · Diphtheria (5) · Haemophilus Infections (5) · Malaria (5) · Tetanus (5) · Chickenpox (3) · Measles (3) · Mumps (3) · Rubella (3) · Acquired Immunodeficiency Syndrome (2) · Diarrhea (2) · Salmonella Infections (2)
Sanofi Pasteur, a Sanofi Company (41) · GlaxoSmithKline (25) · University of Oxford (6) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Novartis Vaccines (4) · Sanofi (4) · Serum Institute of India Pvt. Ltd. (3) · EuBiologics Co.,Ltd (2) · Public Health England (2) · Biogen (1) · Brigham and Women's Hospital (1) · CanSino Biologics Inc. (1) · Canadian Immunization Research Network (1) · Centers for Disease Control and Prevention (1) · EyeGene Inc. (1)
United States (47) · United Kingdom (11) · Canada (10) · Puerto Rico (10) · Belgium (6) · Mali (6) · South Korea (6) · Australia (5) · India (5) · Finland (4) · Mexico (4) · Russia (4) · Turkey (Türkiye) (4) · Argentina (3) · Brazil (3)
Patrick E Duffy, M.D. (3) · Adrian VS Hill, PhD (1) · Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1) · Andrew J Pollard, FRCPCH, PhD (1) · Andrew Pollard, FRCPCH, PhD (1) · Andrew Pollard, Prof (1) · Catherine Cosgrove, MBBS PhD (1) · Dan L. Longo, MD (1) · Dr Prasad Kulkarni, MD (1) · Elizabeth Miller, MD (1) · Eric Stern, MD (1)
PMID 39787798, PMID 36369456, PMID 16203934, PMID 16417952, PMID 17072120, PMID 20943209, PMID 21134450, PMID 22094635, PMID 24567843, PMID 25285126, PMID 25969894, PMID 26075813, PMID 27642132, PMID 28965718, PMID 29159204, PMID 29550195, PMID 29778515, PMID 30061029, PMID 30061051, PMID 30120069, PMID 31307393, PMID 31634044, PMID 31877141, PMID 32209015, PMID 32209248, PMID 32233961, PMID 32387012, PMID 32852352, PMID 33220855, PMID 33306989, PMID 33335323, PMID 33439463, PMID 33561016, PMID 33617777, PMID 33798499, PMID 34077644, PMID 34153264, PMID 34480858, PMID 34787449, PMID 35192543, PMID 35257644, PMID 36875126, PMID 37027391, PMID 37088964, PMID 37172200, PMID 37224196, PMID 37256991, PMID 37256992, PMID 37402153, PMID 37477875
2017 (4), 2016 (3), 2018 (3), 2019 (3), 2023 (1)